Warner Chilcott plc
WCRX today announced that the United States Food and Drug
Administration (FDA) has approved its new 400 mg mesalamine product indicated
for the treatment of ulcerative colitis. The product will be marketed as
DELZICOL™ (mesalamine) 400 mg delayed-release capsules. The Company
anticipates that it will commercially launch DELZICOL in March 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in